Aurora Kinase/Cdk Inhibitor-CAS 443797-96-4-Calbiochem

C₁₅H₁₂F₂N₆O₃S · xC₂H₃N

394.36

A cell-permeable triazolylsulfonamido compound that acts a reversible, ATP-competitive kinase inhibitor with selectivities towards Aurora kinases (IC₅₀ = 11 and 15 nM for Aurora-A, Aurora-B, respectively) and Cdk′s (IC₅₀ = 9, 4, and 3 nM for Cdk1/B, Cdk2/A, and Cdk2/E, respectively). Displays antitumor properties both in vitro (IC₅₀ in the range of 112-514 nM against various human cancer cell lines) and in a xenograft murine model in vivo (75-100 mg/kg, i.p.).
A cell-permeable triazolylsulfonamido compound that acts a reversible, ATP-competitive kinase inhibitor with selectivities towards Aurora kinases (IC₅₀ = 11 and 15 nM for Aurora-A, Aurora-B, respectively) and Cdk′s (IC₅₀ = 9, 4, and 3 nM for Cdk1/B, Cdk2/A, and Cdk2/E, respectively). Displays antitumor properties both in vitro (IC₅₀ in the range of 112 - 514 nM against various human cancer cell lines) and in a xenograft murine model in vivo (75-100 mg/kg, i.p.).

Cell permeable: yes
Target IC₅₀: 11 and 15 nM for Aurora-A, Aurora-B, respectively; 9, 4, and 3 nM for Cdk1/B, Cdk2/A, and Cdk2/E, respectively
Product competes with ATP.
Reversible: yes
Primary Target
Aurora Kinase/Cdk

Toxicity: Harmful (C)

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Emanuel, S., et al. 2005. Cancer Res.65, 9038.
Lin R., et al. 2005. J. Med. Chem.48, 4208.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

100

≥97% (HPLC)

solid

Calbiochem^®

OK to freeze
protect from light

white

DMSO: 15 mg/mL

ambient

2-8℃

5 mg in Plastic ampoule
Packaged under inert gas

11 - Combustible Solids

WGK 2